NasdaqGM:SUPNPharmaceuticals
Supernus Pharmaceuticals (SUPN): Evaluating Valuation After Strong Q3 Growth, Margin Pressure, and Updated 2025 Outlook
Supernus Pharmaceuticals (SUPN) saw a jump in third-quarter sales, fueled by the momentum of Qelbree, GOCOVRI, and the launch of ONAPGO. The company boosted its full-year 2025 revenue outlook following these results.
See our latest analysis for Supernus Pharmaceuticals.
Despite impressive third-quarter results and a boosted product pipeline, Supernus Pharmaceuticals shares experienced a steep pullback after the recent earnings announcement. The 7-day share price return dropped 16.5%,...